MELI vs PFE: Which Is the Better Buy?
Side-by-side comparison of MercadoLibre, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
MercadoLibre, Inc. · Consumer Cyclical
$1,828.94
+25.8% upside to fair value
Med Conviction
Grade B+
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
MELI has more upside to fair value
(+25.8%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MELI |
PFE |
| Current Price |
$1,828.94 |
$27.64 |
| Fair Value Estimate |
$2,300.00 |
$30.94 |
| Upside to Fair Value |
+25.8%
|
+12.0%
|
| Market Cap |
$92.7B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
33.0x
|
17.4x
|
| Price / Sales |
2.6x
|
2.5x
|
| Price / FCF |
7.4x
|
14.3x
|
| Revenue Growth YoY |
+49.8%
|
+2.6%
|
| Gross Margin |
42.7%
|
71.3%
|
| Operating Margin |
8.3%
|
25.1%
|
| Return on Equity |
26.5%
|
4.9%
|
| Dividend Yield |
0% |
6.22% |
| FCF Yield |
13.44%
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
MercadoLibre operates Latin America's leading ecommerce marketplace alongside Mercado Pago payments, credit, logistics, advertising and loyalty products, creating a broad ecosystem with meaningful network effects and cross-sell. Business momentum remains strong: revenue and financial income grew 49.8% year over year in the most recent quarter to $10.169 billion, GMV increased 44%, TPV rose 56%, a…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
MELI |
PFE |
| Zone Low |
$1,725.00 |
$23.21 |
| Zone High |
$1,955.00 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|